The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
- PMID:1603139
- DOI:10.1056/NEJM199207093270203
The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
Abstract
Background:Primary pulmonary hypertension is a progressive, fatal disease of unknown cause. Vasodilator drugs have been used as a treatment, but their efficacy is uncertain.
Methods:We treated 64 patients with primary pulmonary hypertension with high doses of calcium-channel blockers. Patients who responded to treatment (defined as those whose pulmonary-artery pressure and pulmonary vascular resistance immediately fell by more than 20 percent after challenge) were treated for up to five years. Their survival was compared with that of the patients who did not respond and with patients enrolled in the National Institutes of Health (NIH) Registry on Primary Pulmonary Hypertension. Warfarin was given to 55 percent of the patients as concurrent therapy, on the basis of a lung scan showing nonuniformity of pulmonary blood flow (47 percent of patients who responded and 57 percent of those who did not respond).
Results:Seventeen patients (26 percent) responded to treatment, as indicated by a 39 percent fall in pulmonary-artery pressure and a 53 percent fall in the pulmonary-vascular-resistance index (P less than 0.001). Nifedipine (mean [+/- SD] daily dose, 172 +/- 41 mg) was given to 13 patients, and diltiazem (mean daily dose, 720 +/- 208 mg) was given to 4 patients. After five years, 94 percent of the patients who responded (16 of 17) were alive, as compared with 55 percent of the patients who did not respond (26 of 47, P = 0.003). The survival of the patients who responded was also significantly better than that of the NIH registry cohort (P = 0.002) and patients from the NIH registry who were treated at the University of Illinois (P = 0.001). The use of warfarin was associated with improved survival (P = 0.025), particularly in the patients who did not respond.
Conclusions:This study suggests that high doses of calcium-channel blockers in patients with primary pulmonary hypertension who respond with reductions in pulmonary-artery pressure and pulmonary vascular resistance may improve survival over a five-year period.
Comment in
-
Correction: calcium-channel blockers in primary pulmonary hypertension.N Engl J Med. 1992 Nov 12;327(20):1458-9. doi: 10.1056/NEJM199211123272013. N Engl J Med. 1992. PMID:1285785 Clinical Trial. No abstract available.
-
Endothelial dysfunction in pulmonary hypertension.N Engl J Med. 1992 Jul 9;327(2):117-9. doi: 10.1056/NEJM199207093270209. N Engl J Med. 1992. PMID:1603118 No abstract available.
Similar articles
-
Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.Circulation. 2005 Jun 14;111(23):3105-11. doi: 10.1161/CIRCULATIONAHA.104.488486. Epub 2005 Jun 6. Circulation. 2005. PMID:15939821
-
Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.N Engl J Med. 1998 Jan 29;338(5):273-7. doi: 10.1056/NEJM199801293380501. N Engl J Med. 1998. PMID:9445406 Clinical Trial.
-
Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension.J Am Coll Cardiol. 1993 Feb;21(2):413-8. doi: 10.1016/0735-1097(93)90683-r. J Am Coll Cardiol. 1993. PMID:8426006
-
[Therapy of primary pulmonary arterial hypertension: current status].Schweiz Med Wochenschr. 1994 Oct 1;124(39):1701-7. Schweiz Med Wochenschr. 1994. PMID:7939536 Review. German.
-
The role of calcium channel blockers, steroids, anticoagulation, antiplatelet drugs, and endothelin receptor antagonists.Pediatr Crit Care Med. 2010 Mar;11(2 Suppl):S46-52. doi: 10.1097/PCC.0b013e3181c76bab. Pediatr Crit Care Med. 2010. PMID:20216164 Review.
Cited by247articles
-
Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension.Biomedicines. 2022 Jan 13;10(1):170. doi: 10.3390/biomedicines10010170. Biomedicines. 2022. PMID:35052850 Free PMC article. Review.
-
Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway.Front Pharmacol. 2021 Nov 12;12:767002. doi: 10.3389/fphar.2021.767002. eCollection 2021. Front Pharmacol. 2021. PMID:34867394 Free PMC article. Review.
-
A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities.Blood Res. 2021 Dec 31;56(4):229-242. doi: 10.5045/br.2021.2021117. Blood Res. 2021. PMID:34776414 Free PMC article. Review.
-
Perioperative Management of Pulmonary Hypertension. a Review.J Crit Care Med (Targu Mures). 2021 May 12;7(2):83-96. doi: 10.2478/jccm-2021-0007. eCollection 2021 Apr. J Crit Care Med (Targu Mures). 2021. PMID:34722909 Free PMC article.
-
Update on the Treatment of Pulmonary Arterial Hypertension.Arq胸罩心功能杂志。2021年10月11日7(4):750-764. doi: 10.36660/abc.20200702. Arq Bras Cardiol. 2021. PMID:34709302 Free PMC article. Review. English, Portuguese.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical